Progress on the role of PRMTs in hematological malignancy diseases
10.3760/cma.j.issn.1673-4408.2023.09.004
- VernacularTitle:蛋白质精氨酸甲基转移酶在血液肿瘤疾病中的作用研究进展
- Author:
Hongbo HE
1
;
Huyong ZHENG
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院血液病中心 儿童血液病与肿瘤分子分型北京市重点实验室 儿童血液病国家临床重点专科 儿科学国家重点学科 儿科重大疾病研究教育部重点实验室 100045
- Keywords:
Protein arginine methyltransferases;
Hematological malignancy diseases
- From:
International Journal of Pediatrics
2023;50(9):590-594
- CountryChina
- Language:Chinese
-
Abstract:
The protein arginine methyltransferases(PRMTs)family has a wide range of molecular functions and is involved in the generation, development, proliferation and differentiation of hematopoietic cells in the stem cell development.In hematological malignancy diseases, PRMTs can be involved in many important biological processes including cell proliferation, cell cycle, gene transcription, and DNA damage repair through methylation pathways.The abnormal expression of PRMTs can lead to the occurrence and development of malignancy diseases, especially in childhood leukemia.Targeted PRMTs therapy can effectively inhibit the proliferation and survival of tumor cells by reducing the expression of PRMTs.Therefore, the relationship between PRMTs and hematological malignancy diseases has received much attention and is likely to become an important target for treatment in the future.This article reviews the role and mechanism of PRMTs in hematological malignancy diseases, in order to provide new strategies for the treatment of hematological malignancy diseases.
